|| Aarkstore.com Latest Report || Autoimmune Disorders Therapeutics Market to 2017 - Launch

Document Sample
|| Aarkstore.com Latest Report || Autoimmune Disorders Therapeutics Market to 2017 - Launch Powered By Docstoc
					Aarkstore.com announces, The Latest market research report is available in
its vast collection:

Autoimmune Disorders Therapeutics Market to 2017 - Launch of
Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis
and Systemic Lupus Erythematosus Therapeutic Segments


http://www.aarkstore.com/reports/Reportid-201970.html


RSS Link of GBI Research
http://www.aarkstore.com/feeds/GBI.xml



Summary

GBI Research, the leading business intelligence provider, has released its latest
research “Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya
and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus
Erythematosus Therapeutic Segments”, which provides insights into autoimmune
disease therapeutics market until 2017. The report is built using data and
information sourced from proprietary databases, primary and secondary research
and in-house analysis by GBI Research’s team of industry experts. The report
provides in-depth analysis of the main autoimmune diseases, which are Rheumatoid
Arthritis (RA), Multiple Sclerosis (MS), Psoriasis, Inflammatory Bowel Disease (IBD)
including Crohn’s Disease (CD) and Ulcerative Colitis (UC), and Systemic Lupus
Erythematosus (SLE). The report also gives the share of generic drugs in global
autoimmune diseases, as well as in each indication’s market.

Scope

- Data and analysis on the autoimmune diseases therapeutics market in the leading
geographies: the US, the top five countries of Europe (the UK, Germany, France,
Italy, Spain), and Japan.
- Annualized market data for the autoimmune diseases therapeutics market from
2002 to 2010, and forecast from 2010 to 2017.
Table of Contents :

1.1 List of Tables 6
1.2 List of Figures 9
2 Autoimmune Disorders Therapeutics Market to 2017 - Introduction 12
2.1 GBI Research Report Guidance 13
3 Autoimmune Disorders Therapeutics Market to 2017 - Market Overview 14
3.1 Introduction 14
3.1.1 Revenue 14
3.1.2 Annual Cost of Treatment 15
3.1.3 Treatment Usage Pattern 16
4 Autoimmune Disorders Therapeutics Market to 2017: Geographical Landscape 18
4.1 Revenue Analysis by Geography 18
4.2 The US 19
4.2.1 Revenue 19
4.2.2 Annual Cost of Treatment 20
4.2.3 Treatment Usage Patterns 21
4.3 Top Five Countries of Europe 23
4.3.1 Revenue 23
4.3.2 Revenue by Country 24
4.3.3 Annual Cost of Treatment 25
4.3.4 Treatment Usage Patterns 26
4.4 Japan 28
4.4.1 Revenue 28
4.4.2 Annual Cost of Treatment 29
4.4.3 Treatment Usage Patterns 30
5 Autoimmune Disorders Therapeutics Market to 2017: Therapeutic Landscape 32
5.1 Rheumatoid Arthritis Therapeutics Market 32
5.1.1 Introduction 32

List of Figures

List of Tables are also include.

For more related Reports Plz follow The link:
Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for
Approved Products Reflects a Pessimistic R&D Future

Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011
will Negatively Impact Dyslipidemia Market Value

Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix,
Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth



Search More Reports Related to This Category :

http://www.aarkstore.com/search/viewresults.asp?search=Energy&PubId=&pagen
um=1




For More details Plz do contact :

Sonia

Phone:08149852585

Email: enquiry@aarkstore.com

Our Website :www.aarkstore.com

Facebook: http://www.facebook.com/aarkstore

Linkedin: http://in.linkedin.com/in/aarkstore

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:2
posted:5/10/2012
language:
pages:3
Description: GBI Research, the leading business intelligence provider, has released its latest research “Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments”, which provides insights into autoimmune disease therapeutics market until 2017.